ERT Basics - Enzyme Power-Up
Error generating content for this concept group: Failed to process successful response
ERT Applications - Disease Demolishers
ERT is a key therapeutic strategy for several Lysosomal Storage Diseases (LSDs), involving intravenous administration of recombinant human enzymes to restore deficient activity and ameliorate systemic, non-neurological symptoms.
- ๐ Mnemonic for common ERT-treatable LSDs: We Feel Good Playing Music (Fabry, Gaucher, Pompe, MPS).
| Disease | Deficient Enzyme | Recombinant Enzyme (Generic Name) | Key Clinical Benefits/Targets |
|---|---|---|---|
| Gaucher Disease (Type 1) | Glucocerebrosidase | Imiglucerase, Velaglucerase alfa | โ Hepatosplenomegaly, โ hematology, โ bone disease |
| Fabry Disease | ฮฑ-Galactosidase A | Agalsidase alfa/beta | โ Pain, stabilize renal/cardiac function, โ Gb3 accumulation |
| Pompe Disease | Acid ฮฑ-glucosidase (GAA) | Alglucosidase alfa | โ Muscle function/survival, โ cardiomyopathy, โ glycogen |
| MPS I (Hurler/Scheie) | ฮฑ-L-Iduronidase | Laronidase | โ Organomegaly, โ mobility, improved respiration, โ GAGs |
| MPS II (Hunter) | Iduronate-2-sulfatase | Idursulfase | โ Organomegaly, โ walking, airway improvement, โ GAGs |
| MPS VI (Maroteaux-Lamy) | Arylsulfatase B | Galsulfase | โ Endurance, โ GAGs, improved joints/growth |
โญ Imiglucerase, for Gaucher disease, was one of the pioneering and highly successful ERTs, significantly improving hematological and visceral manifestations.
ERT Realities - Upsides & Hurdles
Upsides (Advantages):
- Addresses the fundamental cause: the primary enzyme defect.
- Proven efficacy: Improves key somatic manifestations (e.g., organomegaly, skeletal dysplasia) in many LSDs.
- Enhances overall quality of life and can significantly โ patient survival.
Hurdles (Disadvantages & Challenges):
- High Cost: Extremely expensive, representing a lifelong financial burden.
- Administration: Requires lifelong, frequent (typically bi-weekly) intravenous (IV) infusions.
- Immunogenicity:
- Common development of anti-drug antibodies (ADAs).
- Neutralizing antibodies (NAbs) can โ efficacy or cause severe infusion reactions.
- Limited Biodistribution:
- Poor penetration of the Blood-Brain Barrier (BBB), thus limiting CNS therapeutic effects.
- Restricted access to poorly vascularized tissues (cornea, bone, cartilage).
- Variable Patient Response: Efficacy and outcomes differ among individuals.
- Infusion-Associated Reactions (IARs): Potential for mild to severe reactions.
Strategies to Overcome Challenges:
- Immune tolerance induction (ITI) protocols to mitigate ADA responses.
- Enzyme engineering for enhanced ERTs:
- PEGylation ($PEG-enzyme$): โ circulatory half-life, โ immunogenicity.
- Altered glycosylation: for improved cellular uptake/targeting and reduced immunogenicity.
- Next-generation ERTs: aiming for improved biodistribution, stability, and lower immunogenicity.
โญ The development of neutralizing antibodies against the recombinant enzyme is a significant concern that can compromise the long-term efficacy of ERT.
HighโYield Points - โก Biggest Takeaways
- ERT supplies functional enzymes for enzyme deficiencies, mainly Lysosomal Storage Disorders (LSDs).
- Treats Gaucher, Fabry, Pompe disease, and Mucopolysaccharidoses (MPS).
- Administered via regular intravenous (IV) infusions, often lifelong.
- Challenges: High cost, immunogenicity, and poor Blood-Brain Barrier (BBB) penetration.
- Improves somatic symptoms and organ function but is not curative.
- Example: Imiglucerase for Gaucher disease.
- Manages symptoms; does not correct the underlying genetic defect.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING โ FREEor get the app
